PPIDT00203
Drug Information
| Name | Pertuzumab |
|---|---|
| Sequence | DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| DrugBank_ID | DB06366 |
| Type | biotech |
| Indication | Pertuzumab is indicated for intravenous administration in combination with [trastuzumab] and [docetaxel] for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.[L14747] It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen[L14747] and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.[L14747] Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and [hyaluronidase] - in the treatment of HER2-positive breast cancers in adults.[L14510] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
30 MG/ML
|
| Injection, solution, concentrate | Intravenous |
30 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
420 mg/14ml
|
| Injection, solution, concentrate | Intravenous |
420 MG
|
| Injection, solution, concentrate | Intravenous; Parenteral |
420 MG
|
| Solution | Intravenous |
420 mg / 14 mL
|
| Solution | Intravenous |
420.000 mg
|
| Injection, solution, concentrate | Parenteral |
420 mcg/14mL
|
| Injection, solution, concentrate | Intravenous |
|
| Solution | Intravenous |
30 mg/ml
|
| Kit; powder, for solution; solution | Intravenous |
|
| Solution, concentrate | Intravenous |
42000000 mg
|
| Injection, solution | Subcutaneous |
|
| Solution | Subcutaneous |
|
| Injection, solution | Subcutaneous |
1200 mg
|
| Injection, solution | Subcutaneous |
600 mg
|
| Solution | Subcutaneous |
6000000 mg
|
| Solution | Intravenous |
420 mg/14ml
|